[{"address1": "545 Concord Avenue", "address2": "Suite 210", "city": "Cambridge", "state": "MA", "zip": "02138", "country": "United States", "phone": "857 702 9600", "website": "https://www.metaviatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. MetaVia Inc. operates as a subsidiary of Dong-A ST Co., Ltd.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. Heon Kim  Hyung", "age": 48, "title": "CEO, President & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 716404, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marshall H. Woodworth", "age": 66, "title": "Chief Financial Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 565684, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mi-Kyung  Kim", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Homolka", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. W. Christopher Fang M.D.", "title": "Consulting Chief Medical Officer & Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael C. Pine", "age": 48, "title": "Senior Vice President of Business Development Advisor", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.315, "open": 7.7, "dayLow": 7.22, "dayHigh": 8.47, "regularMarketPreviousClose": 7.315, "regularMarketOpen": 7.7, "regularMarketDayLow": 7.22, "regularMarketDayHigh": 8.47, "payoutRatio": 0.0, "beta": 0.286, "volume": 158278, "regularMarketVolume": 158278, "averageVolume": 250586, "averageVolume10days": 38284, "averageDailyVolume10Day": 38284, "bid": 0.5715, "ask": 0.6352, "bidSize": 1, "askSize": 1, "marketCap": 207820256, "fiftyTwoWeekLow": 6.05, "fiftyTwoWeekHigh": 30.25, "allTimeHigh": 1424941.4, "allTimeLow": 6.05, "fiftyDayAverage": 9.755132, "twoHundredDayAverage": 9.781796, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3807184, "profitMargins": 0.0, "floatShares": 725431, "sharesOutstanding": 25400000, "sharesShort": 44293, "sharesShortPriorMonth": 1832, "sharesShortPreviousMonthDate": 1760486400, "dateShortInterest": 1763078400, "sharesPercentSharesOut": 0.0018000001, "heldPercentInsiders": 0.62511003, "heldPercentInstitutions": 0.07116, "shortRatio": 0.17, "shortPercentOfFloat": 0.0047999998, "impliedSharesOutstanding": 25400000, "bookValue": 2.876, "priceToBook": 2.844889, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -16216000, "trailingEps": -10.45, "lastSplitFactor": "1:11", "lastSplitDate": 1764892800, "enterpriseToEbitda": -0.221, "52WeekChange": -0.67939264, "SandP52WeekChange": 0.13287461, "quoteType": "EQUITY", "currentPrice": 8.1819, "targetHighPrice": 230.99998, "targetLowPrice": 54.99999, "targetMeanPrice": 156.74998, "targetMedianPrice": 170.49998, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 14283000, "totalCashPerShare": 6.488, "ebitda": -17228000, "totalDebt": 79000, "quickRatio": 1.694, "currentRatio": 1.737, "debtToEquity": 1.248, "returnOnAssets": -0.58407, "returnOnEquity": -1.68181, "freeCashflow": -11055375, "operatingCashflow": -16310000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MTVA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 11.85099, "regularMarketPrice": 8.1819, "postMarketTime": 1764982799, "regularMarketTime": 1764968400, "exchange": "NCM", "messageBoardId": "finmb_630763379", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1470403800000, "postMarketChangePercent": 74.749146, "postMarketPrice": 14.2978, "postMarketChange": 6.1159, "regularMarketChange": 0.86689997, "regularMarketDayRange": "7.22 - 8.47", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 250586, "fiftyTwoWeekLowChange": 2.1318998, "fiftyTwoWeekLowChangePercent": 0.35238013, "fiftyTwoWeekRange": "6.05 - 30.25", "fiftyTwoWeekHighChange": -22.0681, "fiftyTwoWeekHighChangePercent": -0.72952396, "fiftyTwoWeekChangePercent": -67.93926, "dividendDate": 1577750400, "earningsTimestampStart": 1755001800, "earningsTimestampEnd": 1755520200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -10.45, "fiftyDayAverageChange": -1.5732317, "fiftyDayAverageChangePercent": -0.16127221, "shortName": "MetaVia Inc.", "longName": "MetaVia Inc.", "corporateActions": [{"header": "Reverse stock split", "message": "MTVA announces 1 for 11 split effective Dec. 5, 2025", "meta": {"eventType": "SPLIT", "dateEpochMs": 1764910800000, "splitRatio": "1:11"}}], "twoHundredDayAverageChange": -1.5998964, "twoHundredDayAverageChangePercent": -0.16355854, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "NeuroBo Pharmaceuticals, Inc.", "nameChangeDate": "2025-12-05", "cryptoTradeable": false, "marketState": "CLOSED", "displayName": "MetaVia", "trailingPegRatio": null, "__fetch_time": "2025-12-06"}]